ERBB2 and metastatic neoplasm: In 2022, another ADC drug, fam-trastuzumab deruxtecan-nxki (Enhertu), received FDA approval for unresectable or metastatic HER2-low breast cancer patients who had received prior chemotherapy for a metastatic disease or had developed disease relapse during or within six months of finishing adjuvant therapy.